NZ544417A - Management of dementia and neurogenerative diseases with intermediate doses of LHRH antagonists - Google Patents
Management of dementia and neurogenerative diseases with intermediate doses of LHRH antagonistsInfo
- Publication number
- NZ544417A NZ544417A NZ544417A NZ54441702A NZ544417A NZ 544417 A NZ544417 A NZ 544417A NZ 544417 A NZ544417 A NZ 544417A NZ 54441702 A NZ54441702 A NZ 54441702A NZ 544417 A NZ544417 A NZ 544417A
- Authority
- NZ
- New Zealand
- Prior art keywords
- use according
- monthly
- methyl
- lhrh antagonist
- single dose
- Prior art date
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title claims abstract description 20
- 206010012289 Dementia Diseases 0.000 title claims abstract description 8
- 201000010099 disease Diseases 0.000 title claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 3
- 239000002474 gonadorelin antagonist Substances 0.000 claims abstract description 13
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000002045 lasting effect Effects 0.000 claims description 4
- 108700008462 cetrorelix Proteins 0.000 claims description 3
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 3
- 229960003230 cetrorelix Drugs 0.000 claims description 3
- 239000000816 peptidomimetic Substances 0.000 claims description 3
- NOENHWMKHNSHGX-IZOOSHNJSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-IZOOSHNJSA-N 0.000 claims description 2
- KATZUZNTRINHDT-HALMFYTRSA-N (2s)-1-[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]-methylamino]-3-(4-hydroxyphenyl)propanoyl]amino Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 KATZUZNTRINHDT-HALMFYTRSA-N 0.000 claims description 2
- 108010023617 abarelix Proteins 0.000 claims description 2
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 claims description 2
- 229960002184 abarelix Drugs 0.000 claims description 2
- 108010070670 antarelix Proteins 0.000 claims description 2
- 108010083551 iturelix Proteins 0.000 claims description 2
- QRYFGTULTGLGHU-NBERXCRTSA-N iturelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CCCCNC(=O)C=1C=NC=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)CCCNC(=O)C1=CC=CN=C1 QRYFGTULTGLGHU-NBERXCRTSA-N 0.000 claims description 2
- 229950011372 teverelix Drugs 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 235000012208 gluconic acid Nutrition 0.000 claims 3
- 239000000174 gluconic acid Substances 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000000843 powder Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 239000008215 water for injection Substances 0.000 claims 3
- 159000000021 acetate salts Chemical class 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- SMWNCXKOTUSXIC-UHFFFAOYSA-N 1-[7-chloro-3-(3,5-dimethylphenyl)-2-oxo-4-(2-piperidin-2-ylethoxy)-1h-quinolin-6-yl]-3-pyridin-2-ylurea Chemical compound CC1=CC(C)=CC(C=2C(NC3=CC(Cl)=C(NC(=O)NC=4N=CC=CC=4)C=C3C=2OCCC2NCCCC2)=O)=C1 SMWNCXKOTUSXIC-UHFFFAOYSA-N 0.000 claims 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 1
- 238000005516 engineering process Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- NVJDXQUSXGIFBO-UHFFFAOYSA-N pentan-3-yl 2-(2,5-dimethylfuran-3-yl)-8-[(2-fluorophenyl)methyl]-3-[[methyl(2-pyridin-2-ylethyl)amino]methyl]-5-oxoimidazo[1,2-a]pyrimidine-6-carboxylate Chemical compound C12=NC(C3=C(OC(C)=C3)C)=C(CN(C)CCC=3N=CC=CC=3)N2C(=O)C(C(=O)OC(CC)CC)=CN1CC1=CC=CC=C1F NVJDXQUSXGIFBO-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 5
- 102000009151 Luteinizing Hormone Human genes 0.000 description 5
- 108010073521 Luteinizing Hormone Proteins 0.000 description 5
- 229940028334 follicle stimulating hormone Drugs 0.000 description 5
- 229940040129 luteinizing hormone Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000003163 gonadal steroid hormone Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 108700012941 GNRH1 Proteins 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000002483 superagonistic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ544417A true NZ544417A (en) | 2008-03-28 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ544417A NZ544417A (en) | 2001-04-30 | 2002-04-27 | Management of dementia and neurogenerative diseases with intermediate doses of LHRH antagonists |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7288517B2 (enExample) |
| EP (1) | EP1392348B1 (enExample) |
| JP (1) | JP2004529207A (enExample) |
| KR (1) | KR20040000446A (enExample) |
| CN (1) | CN1317030C (enExample) |
| AT (1) | ATE400287T1 (enExample) |
| AU (1) | AU2002310788B2 (enExample) |
| BG (1) | BG108339A (enExample) |
| BR (1) | BR0209290A (enExample) |
| CA (1) | CA2444876A1 (enExample) |
| CZ (1) | CZ20033167A3 (enExample) |
| DE (1) | DE60227507D1 (enExample) |
| DK (1) | DK1392348T3 (enExample) |
| ES (1) | ES2307760T3 (enExample) |
| HU (1) | HUP0400067A2 (enExample) |
| IL (1) | IL156777A0 (enExample) |
| MX (1) | MXPA03008666A (enExample) |
| NO (1) | NO20034322L (enExample) |
| NZ (1) | NZ544417A (enExample) |
| PL (1) | PL362319A1 (enExample) |
| PT (1) | PT1392348E (enExample) |
| RU (1) | RU2319501C2 (enExample) |
| SI (1) | SI1392348T1 (enExample) |
| SK (1) | SK14512003A3 (enExample) |
| UA (1) | UA80679C2 (enExample) |
| WO (1) | WO2002102401A1 (enExample) |
| ZA (1) | ZA200305326B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| CA2415010C (en) * | 2000-07-05 | 2011-05-03 | Yamanouchi Pharmaceutical Co., Ltd. | Propane-1,3-dione derivatives useful as gnrh receptor antagonist |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| AU2005250273B2 (en) * | 2004-06-04 | 2010-10-14 | Astellas Pharma Inc. | Propane-1,3-dione derivative or its salt |
| EP1827468B1 (en) * | 2004-12-23 | 2012-08-22 | Curaxis Pharmaceutical Corporation | Acetylcholinesterase Inhibitors and leuprolide acetate for the treatment of Alzheimer's disease |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| CA2603185C (en) * | 2005-03-31 | 2011-07-26 | Astellas Pharma Inc. | Propane-1,3-dione derivative or salt thereof |
| JP5406030B2 (ja) * | 2006-10-21 | 2014-02-05 | アボット ゲーエムベーハー ウント カンパニー カーゲー | 複素環化合物およびそれらのグリコーゲンシンターゼキナーゼ３阻害薬としての使用 |
| KR20100056509A (ko) * | 2007-09-11 | 2010-05-27 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드의 용도 |
| WO2009033730A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratoires Ag | Peptide gxgrgdspca as a therapeutic agent |
| EP2095818A1 (en) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| US20110129532A1 (en) * | 2008-05-29 | 2011-06-02 | Isr Immune System Regulation Ab | Method and means for treating viral disease, in particular hiv/aids |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| WO1997044339A1 (en) | 1996-05-20 | 1997-11-27 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| EP1185530A1 (en) | 1999-05-14 | 2002-03-13 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) * | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| JP2003512379A (ja) | 1999-10-15 | 2003-04-02 | ニューロクライン バイオサイエンシーズ， インコーポレイテッド | 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法 |
| AU2001248760A1 (en) | 2000-04-13 | 2001-10-30 | Takeda Chemical Industries Ltd. | Preventives/remedies for alzheimer's disease |
| CA2415010C (en) | 2000-07-05 | 2011-05-03 | Yamanouchi Pharmaceutical Co., Ltd. | Propane-1,3-dione derivatives useful as gnrh receptor antagonist |
-
2002
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 EP EP02735312A patent/EP1392348B1/en not_active Expired - Lifetime
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322L/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BG108339A (bg) | 2004-11-30 |
| MXPA03008666A (es) | 2004-10-15 |
| RU2003134949A (ru) | 2005-02-10 |
| SI1392348T1 (sl) | 2008-12-31 |
| HK1072000A1 (en) | 2005-08-12 |
| CN1317030C (zh) | 2007-05-23 |
| NO20034322D0 (no) | 2003-09-26 |
| EP1392348B1 (en) | 2008-07-09 |
| UA80679C2 (en) | 2007-10-25 |
| ES2307760T3 (es) | 2008-12-01 |
| BR0209290A (pt) | 2004-07-13 |
| EP1392348A1 (en) | 2004-03-03 |
| CZ20033167A3 (cs) | 2004-08-18 |
| PT1392348E (pt) | 2008-09-09 |
| US7288517B2 (en) | 2007-10-30 |
| KR20040000446A (ko) | 2004-01-03 |
| RU2319501C2 (ru) | 2008-03-20 |
| SK14512003A3 (sk) | 2004-08-03 |
| JP2004529207A (ja) | 2004-09-24 |
| AU2002310788B2 (en) | 2007-04-05 |
| ATE400287T1 (de) | 2008-07-15 |
| CA2444876A1 (en) | 2002-12-27 |
| WO2002102401A1 (en) | 2002-12-27 |
| ZA200305326B (en) | 2003-07-30 |
| CN1575185A (zh) | 2005-02-02 |
| PL362319A1 (en) | 2004-10-18 |
| IL156777A0 (en) | 2004-02-08 |
| DK1392348T3 (da) | 2008-09-29 |
| NO20034322L (no) | 2003-09-26 |
| US20020177556A1 (en) | 2002-11-28 |
| DE60227507D1 (de) | 2008-08-21 |
| HUP0400067A2 (hu) | 2004-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ544417A (en) | Management of dementia and neurogenerative diseases with intermediate doses of LHRH antagonists | |
| ES2393885T3 (es) | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos | |
| ES2559840T3 (es) | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos | |
| AU2002310788A1 (en) | Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists | |
| EP1663236B1 (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and a biphosphonate | |
| UA129431C2 (uk) | Лікування шкірної форми червоного вовчака | |
| JP2001526217A (ja) | 血管性頭痛に対する局所麻酔薬の新規な使用 | |
| US12268679B1 (en) | Compositions and methods for epidural administration of MCOPPB for pain relief | |
| KR20000029647A (ko) | 양극성장애의치료방법 | |
| HK1072000B (en) | Treatment of alzheimer's diseases with intemediate doses of lhrh antagonists | |
| EP1610771B1 (en) | Use of an alpha2-adrenoceptor antagonist for the treatment of epilepsy | |
| CA3191653A1 (en) | Mepyramine for use in the topical treatment of neuropathic pain | |
| AGENT | 46 BAX 3084 | |
| EP0998923A1 (en) | Use of 5-HT7 receptor agonists for the treatment or prophylaxis of ischemias | |
| HK1090294B (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl] phenyl)pyridine-3-sulphonamide and a biphosphonate | |
| KR20040000460A (ko) | 폐 섬유증 치료용 약제를 제조하기 위한 가트란의 용도 | |
| HK1126131A (en) | Combination comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an lhrh analogue and/or a bisphosphonate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |